- Home
- MNRO vs RIGL Comparison
MNRO vs RIGL Comparison
Compare MNRO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNRO | RIGL |
|---|---|---|
| Founded | 1957 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.9M | 628.4M |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MNRO | RIGL |
|---|---|---|
| Price | $15.64 | $26.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $17.67 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 675.8K | 360.7K |
| Earning Date | 01-28-2026 | 03-03-2026 |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | 0.26 | ★ 19.48 |
| Revenue | ★ $1,195,334,000.00 | $294,282,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.59 | $12.75 |
| P/E Ratio | $62.88 | ★ $1.35 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $12.20 | $15.50 |
| 52 Week High | $23.91 | $52.24 |
Technical Indicators
Market Signals| Indicator | MNRO | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 33.87 | 30.62 |
| Support Level | $13.87 | $24.84 |
| Resistance Level | $16.74 | $30.59 |
| Average True Range (ATR) | 0.74 | 1.04 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 23.80 | 27.12 |
Price Performance
Historical ComparisonAbout MNRO Monro Inc.
Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.